

39,130, 39,131 (2006); *Dominick A. Ricci, M.D.*, 58 FR 51,104, 51,105 (1993); *Bobby Watts, M.D.*, 53 FR 11,919, 11,920 (1988); *Frederick Marsh Blanton*, 43 FR at 27,617.

According to California statute, “[n]o person other than a physician . . . shall write or issue a prescription.” Cal. Health & Safety Code § 11150 (West 2020). Further, “physician,” as defined by California statute, is a person who is “licensed to practice” in California. *Id.* at § 11024.

Here, the undisputed evidence in the record is that Registrant currently lacks authority to practice medicine in California. As already discussed, a physician must be a licensed practitioner to dispense a controlled substance in California. Thus, because Registrant lacks authority to practice medicine in California and, therefore, is not authorized to handle controlled substances in California, Registrant is not eligible to maintain a DEA registration. Accordingly, I will order that Registrant’s DEA registration be revoked.

#### Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. AS6936201 issued to Frederick M. Silvers, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending application of Frederick M. Silvers, M.D. to renew or modify this registration, as well as any pending application of Frederick M. Silvers, M.D. for registration in California. This Order is effective August 27, 2020.

**Timothy J. Shea,**  
Acting Administrator.

[FR Doc. 2020–16343 Filed 7–27–20; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–686]

#### Bulk Manufacturer of Controlled Substances Application: Ampac Fine Chemicals LLC

##### Correction

Notice document 2020–16104, appearing on page 44924 in the issue of Friday, July 24th, 2020, was published as a duplicate of notice document 2020–16104 appearing on pages 44924–44925, and is withdrawn. Notice document 2020–16100, which should have

published Friday, July 24, 2020, is republished elsewhere in this issue.

[FR Doc. C1–2020–16104 Filed 7–27–20; 8:45 am]

**BILLING CODE 1301–00–D**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–683]

#### Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals Virginia, LLC

**Editorial Note:** Notice document 2020–16100, which should have published Friday, July 24, 2020, did not appear in that issue. We are republishing it here in its entirety.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before September 28, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 16, 2020, AMPAC Fine Chemicals Virginia, LLC, 2820 North Normandy Drive, Petersburg, Virginia 23805–2380, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate .....	1724	II
Levomethorphan .....	9210	II
Levorphanol .....	9220	II
Morphine .....	9300	II
Thebaine .....	9333	II
Noroxymorphone .....	9668	II
Tapentadol .....	9780	II

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

**William T. McDermott,**  
Assistant Administrator.

[FR Doc. R1–2020–16100 Filed 7–27–20; 8:45 am]

**BILLING CODE 1301–00–D**

## DEPARTMENT OF JUSTICE

### Notice of Lodging of Proposed Consent Decree Under the Clean Water Act

On July 21, 2020, the Department of Justice lodged a proposed consent decree with the United States District Court for the District of Hawaii in the lawsuit entitled *United States v. Pacific Energy South West Pacific, Ltd.*, Civil Action No. 20–CV–322.

The United States filed this lawsuit under the Clean Water Act. The United States’ complaint seeks injunctive relief and civil penalties for violations of a National Pollutant Discharge Elimination System permit, violations of an administrative order issued by the United States Environmental Protection Agency, and unpermitted discharges of pollutants to waters of the United States at the American Samoa Terminal, a fuel terminal that the defendant Pacific Energy South West Pacific, Ltd., operates in Pago Pago, American Samoa. The consent decree requires the defendant to perform injunctive relief and pay a \$300,000 civil penalty.

The publication of this notice opens a period for public comment on the consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States v. Pacific Energy South West Pacific, Ltd.*, D.J. Ref. No. 90–5–1–1–12086. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email .....	<a href="mailto:pubcomment-ees.enrd@usdoj.gov">pubcomment-ees.enrd@usdoj.gov</a> .
By mail .....	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

During the public comment period, the consent decree may be examined and downloaded at this Justice Department website: <https://www.justice.gov/enrd/consent-decrees>. We will provide a paper copy of the consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for \$11.50 (25 cents per page